Aescap is a Netherlands-based investment firm specializing in biotechnology and life sciences venture investing. The firm focuses on public and private market investments in innovative healthcare and biotech companies, particularly those developing novel therapeutics and medical technologies. It operates with a research-driven approach, leveraging deep scientific analysis to identify high-potential opportunities in drug development and biomedical innovation. Aescap typically invests globally, with a strong emphasis on European and U.S. biotech markets. Its strategy is centered on long-term value creation through exposure to breakthrough medical and scientific advancements.